Ribonucleotide reductases (RNRs) catalyze the conversion of nucleotides to deoxynucleotides in all organisms. The class I RNRs are composed of two subunits, ␣ and , with proposed quaternary structures of ␣22, ␣62, or ␣66, depending on the organism. The ␣ subunits bind the nucleoside diphosphate substrates and the dNTP/ATP allosteric effectors that govern specificity and turnover. The 2 subunit houses the diferric Y • (1 radical per 2) cofactor that is required to initiate nucleotide reduction. 2 ,2 -Difluoro-2 -deoxycytidine (F2C) is presently used clinically in a variety of cancer treatments and the 5 -diphosphorylated F2C (F2CDP) is a potent inhibitor of RNRs. The studies with [1 -3 H]-F2CDP and [5-3 H]-F2CDP have established that F2CDP is a substoichiometric mechanism based inhibitor (0.5 eq F2CDP/␣) of both the Escherichia coli and the human RNRs in the presence of reductant. Inactivation is caused by covalent labeling of RNR by the sugar of F2CDP (0.5 eq/␣) and is accompanied by release of 0.5 eq cytosine/␣. Inactivation also results in loss of 40% of 2 activity. Studies using size exclusion chromatography reveal that in the E. coli RNR, an ␣22 tight complex is generated subsequent to enzyme inactivation by F2CDP, whereas in the human RNR, an ␣66 tight complex is generated. Isolation of these complexes establishes that the weak interactions of the subunits in the absence of nucleotides are substantially increased in the presence of F2CDP and ATP. This information and the proposed asymmetry between the interactions of ␣nn provide an explanation for complete inactivation of RNR with substoichiometric amounts of F2CDP.G emcitabine, or 2Ј,2Ј-difluoro-2Ј-deoxycytidine (F 2 C), is a drug that is used clinically in the treatment of advanced pancreatic cancer and non-small cell lung carcinomas (1-3). In humans, F 2 C enters the cell via CNT-type or ENT-type transporters (4-6) and must be phosphorylated to exhibit its cytotoxicity. The monophosphate of F 2 C (F 2 CMP) is generated by deoxycytidine kinase (7) and is rapidly phosphorylated to the di-and triphosphates (F 2 CDP and F 2 CTP) (8, 9). Diphosphorylated F 2 C (F 2 CDP) is an irreversible inhibitor of ribonucleotide reductase (RNR) (10-13), and F 2 CTP functions as a chain terminator in the DNA polymerase reaction (14, 15). Differentially phosphorylated states of gemzar can also interfere with other enzymes involved in nucleotide metabolism. The mechanisms of cytotoxicity of F 2 C depend on the phosphorylated state of the inhibitor and are likely to be cell specific and multifactoral. Our recent synthesis of [1Ј-3 H]-F 2 CDP has provided the required tool to investigate the mechanism by which this molecule inactivates RNRs. Studies reported herein provide a previously unrecognized approach for RNR inhibition, one in which the mechanism based inhibitor (F 2 CDP) enhances the interactions between the two subunits of RNR preventing nucleotide reduction despite substoichiometric labeling.RNRs catalyze the conversion on nucleoside di(tri)phosphates to de...